Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.
2.

Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.

Sánchez-Ballester F, Miranda P, Lizarraga I, Rejas J, Arumi D.

Actas Urol Esp. 2014 Apr;38(3):156-63. doi: 10.1016/j.acuro.2013.07.008. Epub 2013 Oct 8. English, Spanish.

PMID:
24119382
3.

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.

Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J.

BJU Int. 2010 Jan;105(1):58-66. doi: 10.1111/j.1464-410X.2009.09086.x.

4.

Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.

Ginsberg D, Schneider T, Kelleher C, Van Kerrebroeck P, Swift S, Creanga D, Martire DL.

BJU Int. 2013 Aug;112(3):373-85. doi: 10.1111/bju.12174.

5.

Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.

Rogers RG, Bachmann G, Scarpero H, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T.

Curr Med Res Opin. 2009 Sep;25(9):2159-65. doi: 10.1185/03007990903103279.

PMID:
19601704
6.

Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.

DuBeau CE, Morrow JD, Kraus SR, Creanga D, Bavendam T.

Neurourol Urodyn. 2012 Nov;31(8):1258-65. doi: 10.1002/nau.22252. Epub 2012 Aug 20.

PMID:
22907761
7.

Comparison of fesoterodine and tolterodine in patients with overactive bladder.

Chapple CR, Van Kerrebroeck PE, Jünemann KP, Wang JT, Brodsky M.

BJU Int. 2008 Nov;102(9):1128-32. doi: 10.1111/j.1464-410X.2008.07907.x. Epub 2008 Jul 21.

8.

Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*.

Herschorn S, Heesakkers J, Castro-Diaz D, Wang JT, Brodsky M, Guan Z; Disease Management Study Team.

Curr Med Res Opin. 2008 Dec;24(12):3513-21. doi: 10.1185/03007990802537122 .

PMID:
19032133
9.

Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.

Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z.

BJU Int. 2006 May;97(5):1003-6.

10.

Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.

Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramée C, Capo' JP Jr, Seifeldin R, Forero-Schwanhaeuser S, Nandy I.

Clin Ther. 2008 Oct;30(10):1766-81. doi: 10.1016/j.clinthera.2008.10.011.

PMID:
19014833
11.
12.

Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.

Rovner ES, Rackley R, Nitti VW, Wang JT, Guan Z; 037 Study Group.

Urology. 2008 Sep;72(3):488-93. doi: 10.1016/j.urology.2008.05.019. Epub 2008 Jul 17.

PMID:
18639327
13.

Which anticholinergic drug for overactive bladder symptoms in adults.

Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD005429. doi: 10.1002/14651858.CD005429.pub2. Review.

PMID:
22258963
14.

Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.

Nitti VW, Dmochowski R, Appell RA, Wang JT, Bavendam T, Guan Z; 037 Study Group.

BJU Int. 2006 Jun;97(6):1262-6.

15.

Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial.

Wagg A, Khullar V, Marschall-Kehrel D, Michel MC, Oelke M, Darekar A, Bitoun CE, Weinstein D, Osterloh I.

J Am Geriatr Soc. 2013 Feb;61(2):185-93. doi: 10.1111/jgs.12088. Epub 2013 Jan 25.

PMID:
23350833
16.

Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study.

Wyndaele JJ, Goldfischer ER, Morrow JD, Gong J, Tseng LJ, Guan Z, Choo MS.

Int J Clin Pract. 2009 Apr;63(4):560-7.

18.

Onset of efficacy of tolterodine extended release in patients with overactive bladder.

Sussman DO, Kraus SR, Carlsson M, Guan Z.

Curr Med Res Opin. 2007 Apr;23(4):777-81.

PMID:
17407634
19.

Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.

Coyne KS, Elinoff V, Gordon DA, Deng DY, Brodsky M, Glasser DB, Jumadilova Z, Carlsson M.

Int J Clin Pract. 2008 Jun;62(6):925-31. doi: 10.1111/j.1742-1241.2008.01778.x.

PMID:
18479285
20.

Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial.

Roberts R, Bavendam T, Glasser DB, Carlsson M, Eyland N, Elinoff V.

Int J Clin Pract. 2006 Jun;60(6):752-8.

PMID:
16805764
Items per page

Supplemental Content

Write to the Help Desk